Clinical trials: insulin glargine
Type 2 Diabetes
A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients
This is a phase 3 trial designed to compare the effects of twice daily exenatide plus oral antidiabetic agents (OADs) and once-daily insulin glargine plus OADs with respect to glycemic control, as measured by hemoglobin A1c, with…
- Trial name
- NCT00360334
- Testing
- exenatide, insulin glargine
- Where
- 31 sites in United Kingdom
- Volunteers
- 235 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
Premixed insulin-based therapy is a standard insulin treatment strategy in Austria. The widespread use of premixed insulin is explained by high acceptance by health care professionals and patients due to one single product and…
- Trial name
- LixiBIT (NCT02168491)
- Testing
- Lixisenatide, Insulin glargine
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Diabetes Mellitus, Type 2
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Primary Objective: To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER 2 (NCT03371108)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 57 sites in United States
- Volunteers
- 567 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus, Type 2
Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to investigate the success rate of a switch from insulin therapy to a metformin \& saxagliptin combination in patients with type 2 diabetes mellitus.
- Trial name
- NCT01206647
- Testing
- Metformin and Saxagliptin
- Where
- 7 sites in Germany
- Volunteers
- 120 people
- Sponsor
- ikfe-CRO GmbH
Type 2 Diabetes
Degludec Glargine U300 Hospital Study
Limited data exist about the use of insulin degludec and insulin glargine U300 in the hospitalized patients. A previous study compared the safety and efficacy of insulin degludec versus insulin glargine U100 for the management of…
- Trial name
- NCT05036876
- Testing
- Degludec, Glargine U300
- Where
- India
- Volunteers
- 220 people
- Sponsor
- Medanta, The Medicity, India
Type 2 Diabetes Mellitus, Congestive Heart Failure
Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure
The purpose of this study is to determine if exenatide will improve global cardiac function in patients with type 2 diabetes mellitus and congestive heart failure, by favorable effects on cardiac metabolism leading to improvement…
- Trial name
- NCT00766857
- Testing
- exenatide, Insulin glargine
- Where
- Netherlands
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes
CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial
This exploratory randomized controlled trial evaluates whether a CGM-guided temporary patch pump (CareLevo CSII) reduces glucocorticoid-induced hyperglycemia (GIH) compared to a Lantus-based basal-bolus injection (MDI) regimen in…
- Trial name
- SHIP (NCT07652528)
- Testing
- CareLevo Patch-type Insulin Pump, Insulin Glargine U-100 (Lantus), Fast-acting Insulin Aspart (Fiasp)
- Volunteers
- 50 people
- Sponsor
- Hallym University
Diabetes Mellitus, Type 2
Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes
The purpose of this study is to see what the effects of using one or two additional diabetes drugs (dapagliflozin and exenatide-LAR) are on blood sugar levels in patients who are taking insulin.
- Trial name
- Dexlar (NCT02811484)
- Testing
- Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Diabetes, Diabetes Mellitus, Type 2
Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to compare the 24-hour pharmacodynamics/ pharmacokinetics of biphasic insulin aspart 30 (BiAsp 30) thrice daily treatment with that of a basal-bolus treatment…
- Trial name
- NCT00824668
- Testing
- biphasic insulin aspart 30, insulin glargine, insulin glulisine
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Glulisine + Lantus in Type I Patients
To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR 1964) in subjects with type I diabetes…
- Trial name
- NCT00546702
- Testing
- Insuline Glulisine
- Where
- Russia
- Volunteers
- 142 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin
This is a pilot study to examine and compare the efficacy of supervised injections of long acting insulins degludec and glargine to protect youth with poorly controlled type 1 diabetes (T1D) from development of ketones.
- Trial name
- NCT03400501
- Testing
- Insulin Degludec, Insulin Glargine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Yale University
Diabetes Mellitus
The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus
This is an open-label randomised multicenter clinical study to investigate efficacy, safety, and immunogenicity of the drug products: Insulin Glargine biosimilar ® Log-G and its reference Lantus® in type 2 diabetes mellitus…
- Trial name
- NCT04591457
- Testing
- Insulin Glargine Sansulin, Insulin Glargine Pen Injector [Lantus]
- Where
- Indonesia
- Volunteers
- 120 people
- Sponsor
- Universitas Indonesia
Type 2 Diabetes Mellitus
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Primary Objective: To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) < 7%.
- Trial name
- NCT02545842
- Testing
- INSULIN GLARGINE
- Where
- 44 sites in China
- Volunteers
- 947 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.
Primary Objective: >To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c <= 7% without confirmed nocturnal hypoglycaemia in each treatment group.
- Trial name
- DINAMO (NCT01122979)
- Testing
- INSULIN GLARGINE, NPH insulin (insulin isophane), INSULIN GLULISINE
- Where
- 10 sites in Brazil
- Volunteers
- 72 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Primary Objective: To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area…
- Trial name
- NCT01596504
- Testing
- Lixisenatide (AVE0010), Liraglutide, Insulin Glargine
- Where
- 8 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Sanofi
Type1 Diabetes Mellitus, Type2 Diabetes Mellitus
Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus
- Trial name
- NCT03332849
- Testing
- HM12470
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Study of LY3192767 in Healthy Participants
The main purpose of this study is to investigate the side effects related to LY3192767 when given as an injection under the skin to healthy participants.
- Trial name
- NCT03025009
- Testing
- LY3192767, Basal Insulin Peglispro, Insulin Glargine
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes
The main goals of the study are to evaluate the effect of Exenatide on endothelial-dependent vasodilation, as measured by flow mediated dilation (FMD), to evaluate the effect on endothelial-independent vasodilation, as measured…
- Trial name
- NCT00353834
- Testing
- Exenatide, Glargine Insulin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Joslin Diabetes Center
Type 2 Diabetes Mellitus
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Primary Objective: To demonstrate the superiority of Soliqua 100/33 versus Lantus in the hemoglobin A1c (HbA1c) change within the overall population.
- Trial name
- LixiLan-D (NCT03434119)
- Testing
- Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
- Where
- 85 sites in United States
- Volunteers
- 241 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
This study will compare insulin lispro low mixture [LM] and insulin glargine both in combination with the patient's oral diabetes medicines, for their ability to control blood sugar in patients with type 2 diabetes and compare…
- Trial name
- IOOV (NCT00279201)
- Testing
- Insulin glargine, Lispro Low Mix, Lispro Mid Mix
- Where
- 199 sites in United States, Argentina and 10 more
- Volunteers
- 2,091 people
- Sponsor
- Eli Lilly and Company